Simvastatin reduces CD40 expression in an experimental model of early arterialization of saphenous vein graft.
暂无分享,去创建一个
G. Patti | C. Spadaccio | M. Chello | M. Lusini | E. Covino | A. Anselmi | G. Di Sciascio
[1] R. Lauro,et al. Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients , 2005, Circulation.
[2] R. Zhong,et al. Relationship between expression of CD40-CD40 ligand system and serum cholesterol levels in patients with hypercholesterolemia. , 2004, Chinese medical journal.
[3] P. Aukrust,et al. Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation? , 2004, Journal of the American College of Cardiology.
[4] N. Cheshire,et al. Phenotypic and functional differences between human saphenous vein (HSVEC) and umbilical vein (HUVEC) endothelial cells. , 2004, Atherosclerosis.
[5] T. Lüscher,et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. , 2003, Cardiovascular research.
[6] G. Patti,et al. Pressure distension stimulates the expression of endothelial adhesion molecules in the human saphenous vein graft. , 2003, The Annals of thoracic surgery.
[7] J. Freedman. CD40-CD40L and platelet function: beyond hemostasis. , 2003, Circulation research.
[8] R. Callard,et al. CD40 Is Constitutively Expressed on Platelets and Provides a Novel Mechanism for Platelet Activation , 2003, Circulation research.
[9] C. Heeschen,et al. Soluble CD40 ligand in acute coronary syndromes. , 2003, New England Journal of Medicine.
[10] P. Libby,et al. Oxidized Low-Density Lipoprotein Augments and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Limit CD40 and CD40L Expression in Human Vascular Cells , 2002, Circulation.
[11] M. Hecker,et al. 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase-Independent Inhibition of CD40 Expression by Atorvastatin in Human Endothelial Cells , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[12] J. Shuhaiber,et al. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[13] G. Davı̀,et al. , Hypercholesterolemia : Effects of Statin Therapy Association Between Enhanced Soluble CD 40 L and Prothrombotic State in , 2002 .
[14] H. Gold,et al. Cardiopulmonary Bypass Induces Release of Soluble CD40 Ligand , 2002, Circulation.
[15] W. Daniel,et al. Upregulation of CD40 and CD40 Ligand (CD154) in Patients With Moderate Hypercholesterolemia , 2001, Circulation.
[16] P. Libby,et al. Soluble CD40L and Cardiovascular Risk in Women , 2001, Circulation.
[17] S. Miller,et al. Emerging mechanisms for secondary cardioprotective effects of statins. , 2001, Cardiovascular research.
[18] P. Crean,et al. Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. , 2001, The American journal of cardiology.
[19] A. M. Lefer,et al. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. , 2001, Cardiovascular research.
[20] D. M. Elnicki,et al. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. , 2000, The American journal of cardiology.
[21] R. Phipps. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[22] F. Perticone,et al. Nitric oxide modulation of neutrophil-endothelium interaction: difference between arterial and venous coronary bypass grafts. , 1998, Journal of the American College of Cardiology.
[23] Reinhold Förster,et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.
[24] R. Reneman,et al. Venous myogenic tone and its regulation through K+ channels depends on chronic intravascular pressure. , 1997, Circulation research.
[25] P. Libby,et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? , 1997, Circulation research.
[26] J. Powell,et al. Development of an in vitro model to study the response of saphenous vein endothelium to pulsatile arterial flow and circumferential deformation. , 1997, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[27] F. Ruschitzka,et al. Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels. Implications for venous bypass graft failure. , 1997, Circulation.
[28] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[29] W J Keon,et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. , 1996, Journal of the American College of Cardiology.
[30] P. Kiener,et al. Expression of functional CD40 by vascular endothelial cells , 1995, The Journal of experimental medicine.